Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella pertussis Disease and Infection

Camille Locht, James F Papin, Sophie Lecher, Anne-Sophie Debrie, Marcel Thalen, Ken Solovay, Keith Rubin, Nathalie Mielcarek, Camille Locht, James F Papin, Sophie Lecher, Anne-Sophie Debrie, Marcel Thalen, Ken Solovay, Keith Rubin, Nathalie Mielcarek

Abstract

Evidence suggests that the resurgence of pertussis in many industrialized countries may result from the failure of current vaccines to prevent nasopharyngeal colonization by Bordetella pertussis, the principal causative agent of whooping cough. Here, we used a baboon model to test the protective potential of the novel, live attenuated pertussis vaccine candidate BPZE1. A single intranasal/intratracheal inoculation of juvenile baboons with BPZE1 resulted in transient nasopharyngeal colonization and induction of immunoglobulin G and immunoglobulin A to all antigens tested, while causing no adverse symptoms or leukocytosis. When BPZE1-vaccinated baboons were challenged with a high dose of a highly virulent B. pertussis isolate, they were fully protected against disease, whereas naive baboons developed illness (with 1 death) and leukocytosis. Total postchallenge nasopharyngeal virulent bacterial burden of vaccinated animals was substantially reduced (0.002%) compared to naive controls, providing promising evidence in nonhuman primates that BPZE1 protects against both pertussis disease and B. pertussis infection.

Keywords: baboon model; live attenuated vaccine; pertussis.

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Baboon nasopharyngeal colonization by BPZE1 and leukocytosis. A, Four baboons (solid red line) and 3 baboons (dashed green line) were inoculated with 109 colony-forming units (CFU) and 1010 CFU of BPZE1, respectively, and nasopharyngeal bacterial loads were measured at weekly intervals, as indicated, with a limit of detection of 10 CFU/mL. B, White blood cell (WBC) counts were determined at the indicated time points. Blue, red, and green bars indicate WBC counts of noninfected animals, baboons inoculated with 109 CFU BPZE1, and baboons inoculated with 1010 CFU BPZE1, respectively. Results are presented as geometric mean with geometric standard error of the mean.
Figure 2.
Figure 2.
Serum antibody responses of BPZE1-inoculated baboons. Immunoglobulin G (IgG) (A) and immunoglobulin A (IgA) (B) titers were measured against filamentous hemagglutinin (FHA) (upper panels), pertussis toxin (PT) (middle panels), and pertactin (Prn) (lower panels) at the indicated time points after administration of BPZE1. Each symbol represents an individual animal. Blue, red, and green symbols indicate antibody titers of noninfected animals, baboons inoculated with 109 colony-forming units (CFU) BPZE1, and baboons inoculated with 1010 CFU BPZE1, respectively.
Figure 3.
Figure 3.
BPZE1-induced protection against challenge with Bordetella pertussis strain D420. Juvenile baboons were nasally vaccinated with 109 colony-forming units (CFU) (red symbols) or 1010 CFU BPZE1 (green symbols) or left untreated (blue symbols). Seven weeks after vaccination, all animals were infected with >1010 CFU B. pertussis D420, and white blood cell (WBC) (A) counts were determined at the indicated time points after challenge. Blue, red, and green bars indicate WBC counts of nonvaccinated animals, baboons vaccinated with 109 CFU BPZE1, and baboons vaccinated with 1010 CFU BPZE1, respectively. B, Nasopharyngeal colonization by B. pertussis D420 was monitored at indicated time points. Each symbol represents an individual animal. C, Total bacterial burden was estimated as area under the curve of (B) in nonvaccinated baboons (Control), baboons vaccinated with 109 CFU BPZE1 (109), or baboons vaccinated with 1010 CFU BPZE1 (1010). Results are presented as geometric mean with geometric standard error of the mean. **P < .01.
Figure 4.
Figure 4.
Booster effect of Bordetella pertussis D420 challenge in BPZE1-vaccinated baboons. Immunoglobulin G (IgG) (A) and immunoglobulin A (IgA) (B) titers were measured against filamentous hemagglutinin (FHA) (upper panels), pertussis toxin (PT) (middle panels), and pertactin (Prn) (lower panels) at the indicated time points after challenge with B. pertussis D420. Each symbol represents an individual animal. Blue, red, and green symbols indicate antibody titers of nonvaccinated animals, baboons vaccinated with 109 colony-forming units (CFU) BPZE1, and baboons vaccinated with 1010 CFU BPZE1, respectively.

References

    1. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326–82.
    1. World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85:385–400.
    1. World Health Organization. Global routine vaccination coverage, 2011. Wkly Epidemiol Rec 2012; 87:432–5.
    1. Allen A. The pertussis paradox. Science 2013; 341:454–5.
    1. Burns DL, Meade BD, Messionnier NE. Pertussis resurgence: perspectives from the Working Group Meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge. J Infect Dis 2014; 209(suppl 1):S32–5.
    1. Althouse BM, Scarpino SV. Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med 2015; 13:146.
    1. Zhang Q, Yin Z, Li Y et al. . Prevalence of asymptomatic Bordetella pertussis and Bordetella parapertussis infections among school children in China as determined by pooled real-time PCR: a cross-sectional study. Scand J Infect Dis 2014; 46:280–7.
    1. de Greeff SC, de Melker HE, van Gageldonk PG et al. . Seroprevalence of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One 2010; 5:e14183.
    1. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 2006; 53:106–13.
    1. Palazzo R, Carollo M, Fedele G et al. . Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012–2013) [manuscript published online ahead of print 13 April 2016]. J Med Microbiol 2016. doi:10.1099/jmm.0.000264.
    1. Fine PE, Clarkson JA. The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet 1982; 1:666–9.
    1. Elahi S, Holmstrom J, Gerdts V. The benefits of using diverse animal models for studying pertussis. Trends Microbiol 2007; 15:462–8.
    1. Warfel JM, Zimmerman LI, Merkel TJ. Comparison of three whole-cell pertussis vaccines in the baboon model of pertussis. Clin Vaccine Immunol 2016; 23:47–54.
    1. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A 2014; 111:787–92.
    1. Mielcarek N, Debrie AS, Raze D et al. . Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006; 2:e65.
    1. Locht C, Mielcarek N. Live attenuated vaccines against pertussis. Expert Rev Vaccines 2014; 13:1147–58.
    1. Thorstensson R, Trollfors B, Al-Tawil N et al. . A phase I clinical study of a live attenuated Bordetella pertussis vaccine—BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One 2014; 9:e83449.
    1. Boinett CJ, Harris SR, Langridge GC, Tainor EA, Merkel TJ, Parkhill J. Complete genome sequence of Bordetella pertussis D420. Genome Announc 2015; 3:e00657–15.
    1. Warfel JM, Beren J, Kelly VK, Lee G, Merkel TJ. Nonhuman primate model of pertussis. Infect Immun 2012; 80:1530–6.
    1. Fröhlich J. Beitrag sur Pathologie des Keuchhustens. Jahrb f Kinderh 1897; 44:53–8.
    1. Long SS, Lischner HW, Deforest A, Clark JL. Serologic evidence of subclinical pertussis in immunized children. Pediatr Infect Dis J 1990; 9:700–5.
    1. Bart MJ, Harris SR, Advani A et al. . Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio 2014; 5:e01074.
    1. Heininger U, Cherry JD, Christenson PD et al. . Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany. Vaccine 1994; 12:81–6.
    1. Nagel J, Poot-Scholtens EJ. Serum IgA antibody to Bordetella pertussis as an indicator of infection. J Med Microbiol 1983; 16:417–26.

Source: PubMed

3
Subscribe